March 24, 2020 at 15:00 JST
Ryuichi Morishita, left, an Osaka University professor, speaks at a news conference in Tokyo on March 5 with Ei Yamada, president of AnGes Inc., and Junichi Mineno, an executive of Takara Bio Inc. (Roku Goda)
Japanese biopharmaceutical firm AnGes Inc. said on Tuesday that it and Osaka University had completed development of a DNA vaccine against the new coronavirus and that it would begin testing it in animals soon.
Shares of AnGes surged as much as 17 percent in morning trade in Tokyo, compared with a 5.3 percent gain in the broader market.
AnGes, a drug-discovery company launched out of Osaka University, announced its collaboration with the school on a coronavirus vaccine on March 5. DNA vaccines are produced using an inactivated virus and can manufactured faster than protein-based vaccines, according to the company statement.
Takara Bio Co. is in charge of production of the vaccine and Daicel Corp.’s gene-transfer technology is also being utilized, the statement said.
Global pharma companies are racing to develop vaccines and treatments for coronavirus, which has reached 350,000 cases globally and resulted in over 15,000 deaths.
In Japan, market leader Takeda Pharmaceutical Co. is working on a plasma-derived therapy, while the active ingredient in Fujifilm Holdings Corp.’s Avigan anti-flu drug is being tested as a treatment in China.
The Asahi Shimbun aims “to achieve gender equality and empower all women and girls” through its Gender Equality Declaration.
Let’s explore the Japanese capital from the viewpoint of wheelchair users and people with disabilities with Barry Joshua Grisdale.
This special page portrays the dramatic arrest of Carlos Ghosn and the twists and turns that followed.
This special page reviews what the former Nissan Motor Co. chairman left during his 19 years in Japan.
Baseball star Ichiro Suzuki had much to say on March 21, 2019, the day he hung up his spikes.
This special page details how journalists uncovered shady transactions through Bermuda and other tax havens.